Sarepta Therapeutics (SRPT) Says Exondys-51 List Price to be $300K/Year
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
- JPMorgan (JPM) Reports Q4 EPS of $1.71
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) Says Exondys-51 List Price to be $300K/Year
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Naked Brand Group, Inc. (NAKD) Enters $2M Common Stock Securities Purchase Agreement
- Fiat Chrysler Automobiles (FCAU) Said to Face U.S. Criminal Diesel Emissions Probe - Bloomberg
- Sarepta Therapeutics (SRPT) Surges Amid Update, Conference Slides
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!